Clinical trial · Observational
Eribulin in mTNBC Patients
An Observational, Retrospective Study of Eribulin in Advanced Breast Cancer
NCT04541420CI-TRIAL-00049835completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy and safety of Eribulin in patients with advanced breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Eribulin
- description
- Eribulin 1.4mg/m2 d1,8 iv q3w
Primary outcomes (2)
- measure
- PFS
- timeFrame
- 6 weeks
- description
- Progression free survival
- measure
- Adverse events
- timeFrame
- 6 weeks
- description
- Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: 1. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 2. Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug 2020. 3. Available medical history. Exclusion Criteria: 1\. Incomplete medical history.
References
Publications (0)
Data not yet available
No reference posted for this study.